Karp Capital Management Corp increased its stake in shares of iShares US Pharmaceuticals ETF (NYSEARCA:IHE) by 4.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,057 shares of the company’s stock after purchasing an additional 890 shares during the period. Karp Capital Management Corp’s holdings in iShares US Pharmaceuticals ETF were worth $2,934,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in IHE. Ferguson Wellman Capital Management Inc. acquired a new position in shares of iShares US Pharmaceuticals ETF during the fourth quarter worth $1,485,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of iShares US Pharmaceuticals ETF during the fourth quarter worth $113,000. Oppenheimer & Co. Inc. increased its holdings in shares of iShares US Pharmaceuticals ETF by 4.2% during the fourth quarter. Oppenheimer & Co. Inc. now owns 2,241 shares of the company’s stock worth $315,000 after buying an additional 90 shares in the last quarter. D.A. Davidson & CO. increased its holdings in shares of iShares US Pharmaceuticals ETF by 14.1% during the fourth quarter. D.A. Davidson & CO. now owns 2,625 shares of the company’s stock worth $370,000 after buying an additional 325 shares in the last quarter. Finally, Biegel & Waller LLC bought a new stake in shares of iShares US Pharmaceuticals ETF in the fourth quarter worth $5,408,000.
Shares of iShares US Pharmaceuticals ETF stock traded up $0.17 during trading on Wednesday, hitting $146.35. The company’s stock had a trading volume of 2,108 shares, compared to its average volume of 10,389. iShares US Pharmaceuticals ETF has a 52 week low of $131.91 and a 52 week high of $170.26.
ILLEGAL ACTIVITY WARNING: “Karp Capital Management Corp Grows Stake in iShares US Pharmaceuticals ETF (IHE)” was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://weekherald.com/2019/05/15/karp-capital-management-corp-grows-stake-in-ishares-us-pharmaceuticals-etf-ihe.html.
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Story: What is a capital gain?
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares US Pharmaceuticals ETF (NYSEARCA:IHE).
Receive News & Ratings for iShares US Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares US Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.